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Exercise
Exercise group Control group
PRE POST PRE POST
V02 max Iml/kg/min) 19.6 ± 3 24.9 ± 3* 19.6 ±4 19.3 ± 5
V02 LT Iml/kg/min) 130 ± 3 17.8 ± 2* 12.3 ± 2 12.0 ± 2
Geographic Variation in the Utilization of
Pacemaker Technology
0-64 65+
NTL In = 732) Epi In = 806) NTL(n = 624) Epi In ~ 665)
Male 80% 83% 84% 86%
CAD 65% 71% 89% 84%
Hx CA 49% 45% 41% 42%
Medn EF 0.36 0.33 032 032
NYHA III or IV 15% 17% 19% 19%
Survival at l-yr 95% 90% 90% 85%
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Mark G. Byrne, Mark A. Hlatky. Stanford University, Stanford, California
The goal of this study was to identify differences in perea pita rates of single
and dual-chamber pacemaker implantation and rates of implantation for a
given conduction disorder at the county level in the State of California. Sig-
nificant geographic variation has been documented in the use of coronary
angiography and coronary artery bypass surgery. We used a large database,
the California Discharge Database, during the years 1984-1992 to identify
the diagnostic codes of patients at risk (complete heart block, Mobitz II block,
sinoatrial dysfunction, and other heart block) for a single or dual-chambered
pacemaker in the twelve most populous counties. Rates were calculated by
identifying patients from a given county who received a pacemaker and di-
viding by the county population in age groups '65-80' and 'over 80', while
controlling for a given diagnostic code. These aged groups captured 79%
of all implants IN ~ 2827 in 1984). Implantation rates per diagnosis were
also calculated for a given county. There was variability in implantation rates
among large counties in California with greater than 100 pacemaker implants
in 1984 and 1985. The overall (ventricular + atrioventricular) rate, by county,
was significantly different in the population groups '65-80' (p < 0.005) and
'over 80' (p < 0.0005). If atrial pacemakers were included in the analysis, the
differences in rates persisted; '65-80' (p < 0.005) and 'over 80' (p < 0.002).
For dual chamber implants only there also was significant variability in both
the 65-80 and >80 aged groups (p < 0.00011 among counties. There also
was significant variability in the ratio of dual to single-chamber pacemakers
by county in both age groups (p < 0.0005).
Conclusion: Initial data using a comprehensive database has identified ge-
ographic variability in county rates of pacemaker implantation independent
of diagnosis. This geographic variation in utilization may represent physician
uncertainty in the use of pacemaker technology.
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The improved observed survival with NTL vs. Epi ICDs was significant in
both the 0-64 (p < 0.0001) and the 65+ (p = 0.001) age groups. Even af-
ter adjustment for differences in pt characteristics, and cardiovascular or ar-
rhythmia descriptors, the risk of death was still lower in NTL pts for both
0-64 (p < 0.0001) and 65+ (p = 0.02).
Conclusions; 1) Pts 2: 65 yrs of age benefit as much as younger pts
from NTL devices. 2) At a time when only Epi-type ICD systems were FDA-
approved, preventing access to investigational (and less invasive) NTL device
systems would have denied older pts a greater 1-yr survival compared to that
achievable with an Epi ICD. 3) These results suggest that relevant medical
data should be availableto policy makers and the public to facilitate informed
decisions regarding third-party payment for investigational devices.
ABSTRACfS22A
Repeated Exercise Induced Ischemia Causes
Myocardial Preconditioning
Simon Maybaum, Michaeillan, Jacob Mogilevsky, Dan Tzivoni. Jesselson Heart
Center, Sheare Zedek Medical Center, Jerusalem, Israel
2 3 1 vs 2 1vs 3
Time to 1 mm (sec) 487 593 572 0004 0021
Recovery Time (sec) 259 126 109 00001 000002
Total Ischemic Time Isec) 633 399 430 00001 0002
Double Product at 1 mm 20322 22325 21298 0008 0.163
Exercise Duration (sec) 862 864 885 0887 0.235
*p < 0,5 within and between groups
The increase in V02 max in the trained group paralleled an increase in
maximal cardiac output (11.8 pre vs. 12.8 I/min post p < 0.051, but maximal
cardiac output did not change in controls. None of the hemodynamic pres-
sures at rest or during exercise differed within or between groups. All of the
increase in V02 max occurred during the first month of training, whereas sig-
nificant increases in V02 LT were observed after both months. Both blood
lactate and perceived exertion levels were significantly lower at matched
ramp work rates after raining.
Conclusion. Training benefits occur early in the course of rehabilitation in
CHF and are mediated through increases in maximal cardiac output, but not
central hemodynamic status. Training longer than one month after the onset
of CHF does not increase V02 max further, but may provide further increases
in V02 LT.
Repeated short episodes of coronary occlusion in experimental animals
cause myocardial preconditioning which reduces the extent of further is-
chemia. The purpose of the present study was to assess whether precondi-
tioning also occurs during repeated exercise induced ischemia.
Twenty-six coronary patients with positive exercise tests had 3 treadmill
exercise tests at 30 minutes intervals. Two additional stress tests were per-
formed on each of the previous 2 days, in order to eliminatelreduce the tra in-
ing effect The 1st exercise test was regarded as baseline, while the 2nd (ex-
21 and 3rd (ex-3) were compared to the 1st. Time to 1 mm ST depression
(STD). recovery time (from maximal ischemia to 1 mm STD). total ischemic
time (from 1 mm STD during exercise to regression of ischemia to 1 mml,
double product at 1 mm STD and exercise duration were assessed.
Preconditioning (defined as an improvement of 10% or more) was seen in
2 or more parameters in 76% of the patients.
These data indicate that total ischemic time and recovery time were
markedly reduced and that time to 1 mm STD was prolonged and the double
product at 1 mm of STD (ischemic threshold) was higher in the second exer-
cise. This is the first evidence that myocardial preconditioning occurs during
repeated exercise induced ischemia.
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[901-721 Potential Survival Benefit from Investigational
Devices in Patients >65 Yrs: Lessons from the
Implantable Cardioverter Defibrillator (ICD)
Experience
Michael H. Lehmann, Diana Roberts, Timothy R. Church, PCD Investigators. Sinai
Hospital, Detroit, MI; Medtronic, Inc., Minneapolis, MN
Controversy regarding the issue of Medicare reimbursement for investiga-
tional devices led us to examine the medical implications of this debate. Pt
survival was estimated in a large ICD ("PCD"I clinical investigation spanning
the transition from epicardial (Epi) systems to the less invasive nonthoraco-
tomy lead (NTLI systems (5/89-1/931, a period during which only Epi-type
devices were FDA-approved. Among the 1471 Epi and 1356 NTL implanta-
tions, 1289 (46%) of system recipients were 2:65 yrs of age ("65+") and the
remainder were under age 65 ("0-64"). Cumulative survival at 1-yr was an-
alyzed within age groups, controlling for clinical descriptors (where CAD =
coronary artery disease; CA ~ cardiac arrest; and NYHA = NY Heart Asso-
ciation Functional Class):
Delayed and Incomplete Reversal of Impaired
Metabolic Vasodilation in Patients with Heart
Failure During Long-term Circulatory Support
with a Left Ventricular Assist Device
Stuart D. Katz, Howard Levin, Milton Packer. Columbia University College of
Physicians & Surgeons, New York, NY
Impaired vasodilation in response to metabolic stimuli in the peripheral cir-
culation is an important determinant of exercise intolerance in patients with
congestive heart failure (CHF). The pathogenesis of impaired metabolic va-
sodilation in patients with CHF is uncertain but may be related in part to
chronic reductions in peripheral blood flow in patients with low cardiac out-
put (CO). A left ventricular assist device (LVADI is an implantable mechanical
pump that provides a non-pharmacologic means to markedly Increase CO In
patients with severe CHF for long periods of time. Whether long-term me-
chanical restoration of normal resting CO with an LVAD enhances metabolic
vasodilation in the peripheral circulation of patients with CHF is unknown.
Accordingly, peak forearm blood flow (FBF, mllminll00 ml) after 5 minutes
of brachial artery occlusion (a maximal metabolic vasodilation stimulus) was
measured with venous occlusion plethysmography in 8 patients with NYHA
Class IV CHF (mean age 52 yrs, mean EF 22%) before, and 1 and 8 weeks
(wks) after continuous LVAD support and in 8 normal subjects. Mean arterial
